Analysis of Adverse Events of Dasatinib and Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated Outside Clinical Trials

被引：0
|
作者：
Suh, Koung Jin [1 ,2 ]
Lee, Ji Yun [2 ]
Shin, Dong-Yeop [1 ]
Koh, Youngil [1 ]
Bang, Soo-Mee [3 ]
Yoon, Sung-Soo [1 ]
Park, Seonyang [4 ]
Kim, Inho [1 ]
Lee, Jeong-Ok [2 ]
机构：
[1] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea
[2] Seoul Natl Univ Bundang Hosp, Internal Med, Seongnam, South Korea
[3] Seoul Natl Univ Bundang Hosp, Seongnam, South Korea
[4] Inje Univ, Haeundae Paik Hosp, Internal Med, Busan, South Korea
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1902.1902
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1902
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
    F J Giles
    E Abruzzese
    G Rosti
    D-W Kim
    R Bhatia
    A Bosly
    S Goldberg
    G L S Kam
    M Jagasia
    W Mendrek
    T Fischer
    T Facon
    U Dünzinger
    D Marin
    M C Mueller
    Y Shou
    N J Gallagher
    R A Larson
    F-X Mahon
    M Baccarani
    J Cortes
    H M Kantarjian
    Leukemia, 2010, 24 : 1299 - 1301
  • [22] Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
    Giles, F. J.
    Abruzzese, E.
    Rosti, G.
    Kim, D-W
    Bhatia, R.
    Bosly, A.
    Goldberg, S.
    Kam, G. L. S.
    Jagasia, M.
    Mendrek, W.
    Fischer, T.
    Facon, T.
    Duenzinger, U.
    Marin, D.
    Mueller, M. C.
    Shou, Y.
    Gallagher, N. J.
    Larson, R. A.
    Mahon, F-X
    Baccarani, M.
    Cortes, J.
    Kantarjian, H. M.
    LEUKEMIA, 2010, 24 (07) : 1299 - 1301
  • [23] Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
    Khoury, H. Jean
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Gambacorti-Passerini, Carlo
    Baccarani, Michele
    Kim, Dong-Wook
    Zaritskey, Andrey
    Countouriotis, Athena
    Besson, Nadine
    Leip, Eric
    Kelly, Virginia
    Bruemmendorf, Tim H.
    BLOOD, 2012, 119 (15) : 3403 - 3412
  • [24] Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis
    Li, Sicong
    He, Jinshan
    Zhang, Xinyi
    Cai, Yuchun
    Liu, Jian
    Nie, Xiaoyan
    Shi, Luwen
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [25] Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies
    Wang, Zeng
    Jiang, Liyu
    Yan, Hao
    Xu, Zhifei
    Luo, Peihua
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (04) : 445 - 456
  • [26] Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
    Kim, T. D.
    Rea, D.
    Schwarz, M.
    Grille, P.
    Nicolini, F. E.
    Rosti, G.
    Levato, L.
    Giles, F. J.
    Dombret, H.
    Mirault, T.
    Labussiere, H.
    Lindhorst, R.
    Haverkamp, W.
    Buschmann, I.
    Doerken, B.
    le Coutre, P. D.
    LEUKEMIA, 2013, 27 (06) : 1316 - 1321
  • [27] Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study
    Stagno, Fabio
    Breccia, Massimo
    Annunziata, Mario
    Trawinska, Malgorzata Monika
    Iurlo, Alessandra
    Sgherza, Nicola
    Fava, Carmen
    Gozzini, Antonella
    Luciano, Luigiana
    Carmosino, Ida
    Bonifacio, Massimiliano
    Sora, Federica
    Crescenzi, Sabrina Leonetti
    Crugnola, Monica
    Gugliotta, Gabriele
    Galimberti, Sara
    Bucelli, Cristina
    Colafigli, Gioia
    Feo, Costanzo
    Tiribelli, Mario
    Mauro, Endri
    Rossi, Antonella Russo
    Guarini, Attilio
    Abruzzese, Elisabetta
    Rosti, Gianantonio
    Di Raimondo, Francesco
    Latagliata, Roberto
    ACTA ONCOLOGICA, 2021, 60 (11) : 1527 - 1533
  • [28] Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML)
    Liu-Dumlao, Theresa
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    Jabbour, Elias
    Burger, Jan A.
    Alvarado, Yesid
    Burton, Elizabeth M.
    Trinh, Long Xuan
    Ravandi, Farhad
    Ferrajoli, Alessandra
    O'Brien, Susan
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1188 - 1188
  • [29] Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management
    Cortes, Jorge E.
    Jimenez, Carlos A.
    Mauro, Michael J.
    Geyer, Alex
    Pinilla-Ibarz, Javier
    Smith, B. Douglas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (02): : 78 - 82
  • [30] COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER INATINIB FAILURE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
    Tiribelli, M.
    Bonifacio, M.
    Binotto, G.
    Maino, E.
    Calistri, E.
    De Marchi, F.
    Scaffidi, L.
    Frison, L.
    Medeot, M.
    Ambrosetti, A.
    Semenzato, G.
    Fanin, R.
    HAEMATOLOGICA, 2015, 100 : 132 - 132
12345